top of page
Browse by category
Search


Stigma toward women who lose weight using GLP-1 medications is greater compared to weight loss via diet and exercise
Women who lost weight using GLP-1 medications are judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a ‘shortcut’, according to a study by Georgetown University Medical Center researchers. The study also found higher levels of stigma when the women in sample scenarios were portrayed as white rather than Black. The findings highlight how social narratives about ‘acc


Looking forward to Malaga and IFSO-EC 2026
In this exclusive interview, Professor Luis Ocaña (Hospital Universitario Virgen de la Victoria de Málaga, Spain), IFSO-EC Malaga 2026 Congress President, discusses some of the key highlights at this year’s meeting with a particular focus on the Pre-Congress Courses, the importance medication and surgery, collaboration with SECO (Spanish Society of Bariatric Surgery) and, of course, the sights and sounds of the beautiful city of Malaga... “We have been working with huge enthu


Reach Surgical gains CE Mark for iREACH IRIS, the first powered reusable stapler with Real-Time Firing Curve and 90° Articulation
Reach Surgical, the surgical solutions division of Genesis MedTech, has received CE Mark approval for iREACH IRIS, a next-generation powered stapling platform designed to deliver Real-Time Firing Curve and up to 90° articulation during surgery. iREACH IRIS Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation Unlike conventional powered staplers that provide general firing feedback, iREACH IRIS Real-Time Firing Curve provides a continuous, location-specific force


Genetic variants may reduce blood‑sugar response to GLP‑1 diabetes drugs
More than a quarter of people with Type 2 diabetes take glucagon-like peptide-1 (GLP-1), but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a study by Stanford Medicine scientists and their collaborators. The genetic variants, carried by roughly 10% of the general population, cause a surprising and still mysterious phenomenon that researchers refer to as GLP-1 resistance, in which levels of the hormone GLP-1, which


Bariatric surgery may reduce the overall risk of breast cancer in women with obesity
A systematic review and meta-analysis has indicated that bariatric surgery may reduce the overall risk of breast cancer in women with obesity, according to researchers from China. However, the studies also revealed a paradoxical finding: Despite the overall reduction in risk, the incidence of stage I breast cancer increased in the surgical group. Nevertheless, the study authors acknowledge that as the studies are based on observational data, a causal relationship cannot be co


Study identifies genetic predictors for GLP-1 weight loss efficacy and side effects
Study identifies genetic predictors for GLP-1 weight loss efficacy and side effects A large-scale genome-wide association study (GWAS) has identified genetic predictors for GLP-1 weight loss efficacy and side effects. The findings provide direct evidence that variation in the genes targeted by GLP-1 medications contributes to why people respond differently to GLP-1 therapies. Illustration of the biological pathways for the GLP-1 genetic associations identified by the 23andMe


Study identifies missing link in how the brain regulates appetite
A collaboration between the University of Maryland (UMD) and University of Concepción in Chile has uncovered a communication chain in the brain. The research identified a previously unknown communication chain in the hypothalamus - the region of the brain responsible for regulating hunger and fullness - these findings could eventually point to new ways of targeting appetite-related conditions such as obesity and eating disorders. Brain regulation of appetite. Diagram showing


FDA approves Lilly's Foundayo (orforglipron) GLP-1 pill for weight loss
The FDA has approved Eli Lilly and Company’s Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist (GLP-1ra) that can be taken any time of the day without restrictions on food and water intake. "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with n


French researchers highlight more complex and potentially more morbid types of revisional bariatric surgeries
Researchers in France have identified a significant shift in the country towards more complex and potentially more morbid types of revisional metabolic bariatric surgeries (RMBS), underscoring the need of careful patient selection through preoperative assessment and personalised postoperative management to reduce risks and optimise outcomes in this population. The aim of their observational study was to assess the rate of RMBS in France and to outline the associated complicati


Researchers uncover mechanism explaining how obesity increases cancer risk
Scientists at City of Hope and TGen (part of City of Hope) have explained a major mechanism for why gaining excess weight increases the risk of cancer across multiple organs. The findings emphasise the importance of maintaining a healthy weight from early childhood and propose a potentially more accurate way than body mass index (BMI) to predict the increase in cancer risk associated with obesity. "People have long been told that obesity increases cancer risk, but they are ra
Browse by tag






bottom of page
